A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer.
The calcium-binding protein S100P is overexpressed in various cancers and may contribute to the oncogenic phenotype. This study used mass spectrometry to characterize a novel 9.2-kDa C-terminally truncated form of S100P (t-S100P), and to investigate its potential prognostic value in breast cancer. Univariate analysis demonstrated the association between breast tissue t-S100P levels (n = 148) and conventional pathological markers. Across all tumor samples, high t-S100P was strongly prognostic for poor disease-free survival (P = 0.005), its efficacy confined to lymph node-positive tumors (n = 74, P = 0.007). Matrix-assisted laser desorption/ionization imaging mass spectrometry confirmed differential t-S100P abundance between breast cancer and unaffected adjacent tissue. t-S100P was exclusively located in the cell nucleus of breast cancer tissue, and full-length S100P was essentially undetectable by mass spectrometry. We conclude that t-S100P is the predominant form of S100P in breast cancer tissue and is strongly prognostic for disease-free survival in women with lymph node-positive disease.
Hormones and Cancer Laboratories, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia.
Liping
L
Chung
Hormones and Cancer Laboratories, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia.
Leo
L
Phillips
Hormones and Cancer Laboratories, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia.
Mike Z
MZ
Lin
Department of Breast Endocrine Surgery, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia.
Katrina
K
Moore
Hormones and Cancer Laboratories, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia.
Deborah J
DJ
Marsh
Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Crows Nest, New South Wales 2065, Australia.
Frances M
FM
Boyle
Hormones and Cancer Laboratories, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia. Electronic address: robert.baxter@sydney.edu.au.
Robert C
RC
Baxter
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002135:Calcium-Binding Proteins / Q000032:analysis*; D002467:Cell Nucleus / Q000737:chemistry; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D010446:Peptide Fragments / Q000032:analysis*; D011237:Predictive Value of Tests; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013997:Time Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D002135:Calcium-Binding Proteins; D009363:Neoplasm Proteins; D010446:Peptide Fragments; C103003:S100P protein, human
Biomarker; Breast cancer; Imaging mass spectrometry; Nucleus; S100P